Advances and innovations in dialysis in the 21st century

Postgraduate Medical Journal

Volumn 85, Issue 1000, 2009, Pages 102-107

  Power, A ^a,b   Duncan, N ^a   Goodlad, C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SORBENT;

ARTIFICIAL KIDNEY; DIALYSATE; DIALYSIS MEMBRANE; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; NANOTECHNOLOGY; PERITONEAL DIALYSIS; PORTABLE EQUIPMENT; REVIEW;

BIOCOMPATIBLE MATERIALS; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 63649123014     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.071837     Document Type: Review

References (104)

1. Graham T. Liquid diffusion applied to analysis. Philos Trans R Soc Lond 1861;151:183-224.
2. Abel JJ, Rowntree LG, Turner BB. On the removal of diffusible substances from the circulating blood by means of dialysis. Trans Assoc Am Physicians Phila 1913;XXVIII:51-4.
3. Abel JJ, Rowntree LG, Turner BB. On the removal of diffusible substances from the circulating blood of living animals by dialysis. J Pharmacol Exper Ther Balt 1913-1914;V:275-316.
4. Haas G. Versuche der Blutauswaschung am Lebenden mit Hilfe der Dialyse. Klin Wochenschr 1925;4:13-14.
5. Ganter G. About the elimination of poisonous substances from the blood by dialysis. Munch Med Wochenschr 1923;70:1478-80.
6. Murray JE, Merrill JP, Harrison JH. Renal homotransplantation in identical twins. Surg Forum 1955;6:432.
7. Kolff WJ. First clinical experience with the artificial kidney. Ann Intern Med 1965;62:608-19.
8. Murphy WP Jr, Swan RC Jr, Walter CW, et al. Use of the artificial kidney. III. Current procedures in clinical hemodialysis. J Lab Clin Med 1952;40:436-44.
9. Quinton W, Dillard D, Scribner BH. Cannulation of blood vessels for prolonged hemodialysis. Trans ASAIO 1960;6:104-7.
10. Brescia MJ, Cimino JE, Appel K, et al. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966;275:1089-92.
11. Tenckhoff H, Schechter H. A bacteriologically safe peritoneal access device. Trans ASAIO 1968;14:181.
12. de Francisco A, Pinera C. Insights into anemia management. Contrib Nephrol 2008;161:240-6
13. Bellasi A, Kooienga L, Block GA. Phosphate binders: new products and challenges. Haemodial Int 2006;10:225-34.
14. Ritz E, Dikow R, Gross M. Dialysis, cardiovascular disease, and the future. HaemodialInt 2007;11 :S2-11.
15. United States Renal Data System. Annual data report. http://www.usrds.org/2008/usrds-booklet-08.pdf. (Accessed 20 Nov 2008).
16. UK Renal Registry. Annual report. http://www.renalreg.com/reports/ renal-registry-reports/2007. (Accessed 20 Nov 2008).
17. Grassman A, Gioberge S, Moeller S, et al. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-93.
18. Pannu N, Klarenbach S, Wiebe N, et al. Renal replacement therapy in patients with acute renal failure: a systemic review. JAMA 2008;299:793-805.
19. Scribner BJ, Cole JJ, Ahmad S, et al. Why thrice weekly dialysis? Haemodial Int 2004;8:188-92.
20. Sargent JA, Gotch FA. Mathematical modelling of dialysis therapy. Kidney Int 1980;(Suppl. 10):S2-10.
21. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-19.
22. Anon. NKF K-DOQI Guidelines 2006 Update. II. Clinical practice recommendations for hemodialysis adequacy. http://www.kidney.org/Professionals/ kdoqi/guideline-upHD-PD-VA/hd-rec4.htm (accessed 14 July 2008).
23. Anon. European best practice guidelines for haemodialysis (part 1). Section II:haemodialysis adequacy. Nephrol Dial Tranplant 2002;17(Suppl 7):17-31.
24. Levin N, Greenwood R. Reflections on the HEMO study: the American viewpoint. Nephrol Dial Transplant 2003;18:1059-60.
25. Locatelli F. Dose of dialysis, convection and haemodialysis patients outcome-what the HEMO study doesn't tell us: the European viewpoint. Nephrol Dial Transplant 2003;18:1061-5.
26. DePalma JR, Pecker EA, Maxwell MH. New automatic coil dialyzer system for 'daily' dialysis. Proc Eur Dial Transplant Assoc 1969;6:26-34.
27. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 2001;38:371-6.
28. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective controlled study. J Am Soc Nephrol 2005;16:2778-88.
29. Chan CT, Floras JS, Miller JA, et al. Improvement in ejection fraction by nocturnal hemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 2002;17:1518-21.
30. Ayus JC, Achinger SG, Mizani MR, et al. Phosphorus balance and mineral metabolism with 3h daily hemodialysis. Kidney Int 2007;71 :336-42.
31. Galland R, Traeger J, Arkouche W, et al. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int 2001;60:1555-60.
32. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001;344:102-7.
33. Finkelstein FO, Finkelstein SH, Wuerth D, et al. Effect of home hemodialysis on health-related quality of life measures. Semin Dial 2007;20:265-8.
34. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network Trial Group. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int 2007;71:349-59.
35. Blagg CR. Evolution of the frequency of hemodialysis for acute and chronic renal failure. Nephrol News Issues 2001;15:55-6.
36. Charra B, Terrat JC, Vanel T, et al. Long thrice weekly hemodialysis: the Tassin experience. Int J Artif Organs 2004;27:265-83.
37. Ledebo I. Ultrapure dialysis fluid: how pure is it and do we need it ? Nephrol Dial Transplant 2007;22:20-3.
38. Donauer J, Schweiger C, Rumberger B, et al. Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant 2003;18:1616-22.
39. Canaud B, Wizemann V, Pizzarelli F, et al. Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy. Nephrol Dial Transplant 2001;16:2181- 7.
40. Tattersall J. Clearance of beta-2-microglobulin and middle molecules in haemodiafiltration. Contrib Nephrol 2007;158:201-9.
41. Cioni L, Palmarini D, Pilone N, et al. High-flux hemodiafiltration: 5 years experience. Blood Purif 1989;7:197-202.
42. Canaud B, Bragg-Gresham JL, Marshall MM, et al. Mortality risk for patients receiving hemofiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-93.
43. Jirka T, Cesare S, Di Benedetto A, et al. The impact of on-line haemodiafiltration (HDF) on patient survival: results from a large network database. Nephrol Dial Transplant 2005;20:v18-19.
44. Bolasco P, Altieri P, Andrullin S, et al. Convection versus diffusion in dialysis: an Italian prospective multicentre study. Nephrol Dial Transplant 2003;7:50-4.
45. Penne EL, Blankestijn PJ, CONSTRAST Group, et al. Resolving controversies regarding hemodiafiltration versus hemodialysis: The Dutch Convective Transport Study. Semin Dial 2005;18:47-51.
46. Canaud B, Morena M, Jausson I, et al. Clinical tolerance of on-line HDF and impact on morbidity and cardiovascular risk factors in ESRD patients of 65 and more years old. Project supported by a French National Grant from the Health Ministry (PHRC national), 2004.
47. Winchester JF, Ronco C, Brady JA, et al. The next step from high-flux dialysis:application of sorbent technology. Blood Purif 2002;20:81-6.
48. Ronco C, Brendolan A, Winchester JF, et al. First clinical experience with an adjunctive hemoperfusion device designed specifically to removed β2-microglobulin in hemodialysis. Contrib Nephrol 2001;133:166-73.
49. Bosch T, Wendler T, Duhr C, et al. Ex-vivo biocompatibility of a new β2-microglobulin adsorbent during hemoperfusion with human whole blood. J Am Soc Nephrol 2000;11:257A.
50. Hansen S. Sorbent dialysis in the third millennium. Nephrol News Issues 2006;20:45.
51. Humes HD, Fissell WH, Tiranathagul K. The future of hemodialysis membranes. Kidney Int 2006;69:1115-9.
52. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application ? J Am Soc Nephrol 2005;16:2421-30.
53. Niwa T, Asada H, Tsutsui S, et al. Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. Am J Nephrol 1995;15:463-7.
54. Galli F, Benedetti S, Buoncristiani U, et al. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 2003;64:749-55.
55. Fissell WH, Westover AJ, Humes HD, et al. Initial characterization of a nanoengineered ultrafiltration membrane. J Am Soc Nephrol 2003;13:602A
56. Fissell WH, Manley S, Westover A, et al. Differentiated growth of human renal tubule cells on thin-film and nanostructured materials. ASAIO J 2006;52:221-7.
57. Ronco C, Bowry S. Nanoscale modulation of the pore dimension, size distribution and structure of a new polysulfone-based high-flux dialysis membrane. Int J Artif Organs 2001;24:726-35.
58. Shin M, Matsuda K, Ishii O, et al. Endothelialized networks with a vascular geometry in microfabricated poly (dimethyl siloxane). Biomed Microdev 2004;6:269-78.
59. Humes HD, MacKay SM, Funke AJ, et al. Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int 1999;55 :2502-14.
60. Humes HD, Fissell WH, Weitzel WF, et al. Metabolic replacement of renal function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis 2002;39:1078-87.
61. Fissell WH, Lou L, Abrishami S, et al. Bioartificial kidney ameliorates Gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 2003;14:454-61.
62. Humes HD, Weitzel WF, Bartlett RH, et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004;66:1578-88.
63. Gura V, Beizai M, Azon C, et al. Continuous renal replacement therapy for end-stage renal disease. The wearable artificial kidney(WAK). ContribNephrol2005;149:325-33.
64. Gura V, Beizai M, Ezon C, et al. Continuous renal replacement therapy for congestive heart failure: the wearable continuous ultrafiltration system. ASAIO J 2006;52:59-61.
65. Gura V, Ronco C, Nalesso F, et al. A wearable hemofilter for continuous ambulatory ultrafiltration. Kidney Int 2008;73:497-502.
66. Nissenson AR, Ronco C, Pergamit G, et al. The human nephron filter: toward a continuously functioning, implantable artificial nephron system. Blood Purif 2005;23:269-74.
67. Parikova A, Smit W, Struijk DG, et al. The contribution of free water transport and small pore transport to the total fluid removal in peritoneal dialysis. Kidney Int 2005;68:1849-56.
68. Rodrigues AS, Silva S, Bravo F, et al. Peritoneal membrane evaluation in routine clinical practice. Blood Purif 2007;25:497- 504.
69. Churchill DN. Implications of the Canada-USA (CANUSA) study of the adequacy of dialysis on peritoneal dialysis schedule. Nephrol Dial Transplant 1998;13(Suppl 6):158-63.
70. Amato D, Paniagua R. The ADEMEX study: afterthoughts. Perit Dial Int 2003;23:313-16.
71. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-162.
72. Paniagua R, Amato D, Voneshi E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX a prospective randomised controlled trial. J Am Soc Nephrol 2002;13:1307-20.
73. Churchill DN. The ADEMEX study-make haste slowly. J Am Soc Nephrol 2002;13:1425-32.
74. Brown EA, Davies SJ, Rutherford P, et al, on behalf of the EAP0S group. Survival of functionally anuric patients on automated PD: the European APD 0utcome study. J Am Soc Nephrol 2003;14:2948-57.
75. Wang T, Lindholm B. Beyond CANUSA, D0QI, ADEMEX: what's next? Perit Dial Int 2002;22:555-62.
76. Churchill DN, Thorpe KE, Nolph KD, et al. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 1998;9:1285-92.
77. Davies SJ, Phillips L, Griffiths AM, et al. Impact of peritoneal membrane function on long term clinical outcome in peritoneal dialysis patients. Perit Dial Int 1999;19(Suppl 2):S91-4.
78. Davies SJ. Mitigating peritoneal membrane characteristics in modern PD therapy. Kidney Int Suppl 2006;103:S76-83.
79. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004;66:2437-45.
80. Davies SJ, Phillips L, Naish PF, et al. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001;12:1046-51.
81. Davies SJ, Brown EA, Frandsen NE, et al, on behalf of the EAP0S Study Group. Longitudinal membrane function in functionally anuric patients treated with APD:data from EAP0S on the effects of glucose and icodextrin prescription. Kidney Int 2005;67:1609-15.
82. Davies SJ, Bryan J, Phillips L, et al. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11:498-506.
83. Kawanishi H, for the Long-Term Peritoneal Dialysis Study Group. Encapsulating peritoneal sclerosis in Japan: prospective multi-centre controlled study. Perit Dial Int 2001;21 (Suppl 3):S67-71.
84. Topley N, Coles GA, Williams JD. Biocompatibility studies on peritoneal cells. Perit Dial Int 1994;14(Suppl 3):S21-8.
85. Boulanger E, Grossin N, Wautier MP, et al. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2007;71:126-33.
86. Lee SK, Kim BS, Yang WS, Kim SR, et al. High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney Int 2001;60:55-64.
87. Wong TY, Phillips AO, Witowski J, et al. Glucose mediated induction of TGF-β 1 and MCP-1 in mesothelial cells in vitro is osmolarity and polyol pathway dependent. Kidney Int 2003;63:1404-16.
88. Noh H, Kim JS, Han KH, et al. 0xidative stress during peritoneal dialysis:implications in functional and structural changes in the membrane. Kidney Int 2006;69:2022-8.
89. Sauter M, Cohen CD, Wornle M, et al. ACE inhibitor and AT-1 receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int 2007;27:167-72.
90. Noh H, Hunjoo H, Yu MR, et al. Angiotensin II mediates high glucose induced TGFβ-1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005;25:38-47.
91. Kolesnyk I, Dekker FW, Noordzjj M, et al. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long term PD patients. Perit Dial Int 2007;27:446-53.
92. Mistry CD, Gokal R, Peers E. A randomised multicentre clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solution in CAPD. MIDAS study group. Kidney Int 1994;46:496-503.
93. Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double blind randomised controlled trial. J Am Soc Nephrol 2003;14:2338-14.
94. Davies SJ. Exploring new evidence of the clinical benefits of icodextrin solutions. Nephrol Dial Transplant 2006;21 (Suppl 2):ii47-50.
95. Davies S, Garcia Lopez E, Woodrow G, et al. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomised to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 2008;23:2982-8.
96. Choi HY, Dong KK, Tae HL, et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomised trial. Perit Dial Int 2008;28:174-82.
97. Pajek J, Kveder R, Bren A, et al. Short term benefits of a new bicarbonate/lactate buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomised control study. Perit Dial Int 2008;28:44-52.
98. Fusshoeller A, Marcus P, Grabensee B, et al. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective randomised study. Nephrol Dial Transplant 2004;19:2101-6.
99. Witowski J, Korybalska K, Ksiazek K, et al and the European Balance Trial Group. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004;19:917-24.
100. Fang W, Mulland R, Shah H, et al. Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective crossover single dwell study. Perit Dial Int 2008;28:35-43.
101. Williams J, Topley N, Craig K, et al. The Euro-Balance trial: the effect of a new biocompatible PD fluid (Balance) on the peritoneal membrane. Kidney Int 2004;66:408-18.
102. Bargman JM. New technologies in peritoneal dialysis. Clin J Am Soc Nephrol 2007;2:576-80.
103. Ahmad S, Sehmi JS, Ahmad-Zakhi KH, et al. Impact of a new dialysis solution on peritonitis rates Kidney Int Suppl 2006;103:S63-6.
104. Dell'Aquila R, Rodighiero MP, Spano E, et al. Advances in the technology of automated, tidal and continuous flow peritoneal dialysis. Perit Dial Int 2007;27 (Suppl 2):S130-7.